Inspire Medical Weighs Growth Against Reimbursement Risks

Inspire Medical ((INSP)) has held its Q4 earnings call. Read on for the main highlights of the call.

Inspire Medical’s latest earnings call struck a cautiously optimistic tone, blending strong 2025 financial execution and clear clinical momentum for its Inspire 5 system with heightened anxiety around U.S. reimbursement. Management highlighted solid cash generation, buybacks, and operating leverage, but emphasized that coding shifts and prior-authorization turbulence could weigh on 2026 growth and margin realization.

Revenue Growth

Fourth quarter revenue rose 12% to $269 million, capping a year in which sales climbed 14% to $912 million as existing centers ramped and new centers came online. Management underscored that demand for hypoglossal nerve stimulation remains robust, with procedure growth supported by a broader base of trained centers and surgeons.

Profitability and Earnings Performance

The company delivered positive operating income and earnings in the fourth quarter, marking a notable profitability milestone. Q4 net income per diluted share jumped by $3.51 to $4.66, while full year net income per diluted share climbed by $3.09 to $4.89, reflecting both operating leverage and one-time tax benefits.

Adjusted Earnings and Cash Flow

On an adjusted basis, Q4 net income per diluted share increased $0.51 to $1.65 and full year adjusted EPS rose $0.80 to $2.42, highlighting more normalized underlying performance. Operating cash flow reached $52 million in the fourth quarter and $117 million for the full year, reinforcing the company’s ability to self-fund growth initiatives.

Capital Allocation and Balance Sheet Strength

Inspire Medical executed $50 million of share repurchases in Q4 and $175 million for the full year, signaling confidence in long-term value despite reimbursement noise. The company ended the quarter with $405 million in cash and investments, providing ample flexibility to invest in innovation, commercial expansion, and potential future volatility.

Inspire 5 Clinical and Reliability Performance

Clinically, Inspire 5 is outperforming its predecessor, with shorter surgical times, significantly better inspiratory overlap, and a 79.5% responder rate in the Singapore study versus 66% in the STAR pivotal trial. Reliability also improved in 2025, with device explants at just 0.5% and revisions at 1.5%, helping support physician confidence and adoption.

Successful U.S. Launch Execution

The U.S. rollout of Inspire 5 appears largely complete, with physician training and contracting more than 95% finished and over 90% of centers now implanting the new system. SleepSync onboarding has surpassed 90% of centers, and management expects stable Inspire 5 inventory through 2026, reducing near-term supply risk.

Product and R&D Progress

The company secured FDA approval for 3 Tesla MRI compatibility, a meaningful competitive and practical advantage for patients needing high-strength imaging. It is also testing prior-authorization functionality within SleepSync and announced the Inspire 6 program, which aims to improve adherence via enhanced sleep detection and automatic therapy activation.

Operational Discipline

Operating margins improved in Q4 and for the full year, driven by scale, a richer mix of higher-margin Inspire 5 systems, and tight expense management. Management pointed to a targeted commercial reorganization, including 295 U.S. territories and 275 field clinical representatives, as a foundation for sustainable growth efficiency.

Commercial and Global Footprint

The U.S. remains the growth engine, with Q4 U.S. revenue of $256.9 million representing roughly 95% of total sales and underscoring domestic dependence. To unlock further capacity, the company is expanding provider infrastructure by training advanced practice providers and certifying more surgeons, positioning the network to treat more obstructive sleep apnea patients.

Coding and Reimbursement Uncertainty

A key overhang is reimbursement clarity, as Inspire 5 procedures are expected to transition to CPT 64582 with a -52 modifier, indicating reduced service. Management estimates that the resulting professional fee cut could range from about 10% to as much as 50% of the base rate, varying widely by Medicare Administrative Contractor and payer.

Potential Physician Willingness Impact

Leadership cautioned that a steep reduction in professional fees could blunt physician enthusiasm for Inspire 5 procedures and suppress case volume. Private-practice surgeons, who rely heavily on professional payments, may be especially sensitive, introducing a behavioral risk layer atop the coding mechanics.

WISER Program Disruption

The Medicare WISER prior-authorization pilot in six states has already caused denials and delays, driven by portal issues, AI-related inconsistencies, and coding confusion. These disruptions are expected to weigh particularly on Medicare volumes in the first quarter of 2026, adding a temporary but meaningful headwind.

Widened 2026 Guidance Due to Reimbursement Risk

Reflecting the breadth of potential outcomes from coding changes and physician behavior, management widened its 2026 revenue range to capture scenarios from modest to severe fee reductions. The low end of guidance assumes a 50% professional fee haircut, underscoring how reimbursement policy now directly brackets the company’s growth trajectory.

Inconsistent Claims and Mapping Across MACs

Claims data so far is messy, with some Inspire 5 procedures paid under both CPT 64568 and 64582, while other claims face denial or re-pricing. None of the MACs have fully mapped the -52 modifier into policy, creating near-term billing variability and administrative friction for providers.

Timing Risk for New CPT Code

Management views a new Category I CPT code, with fresh valuation, as the long-term fix, but the process will not take effect until early 2028. That leaves a multi-year window where reimbursement may remain uncertain and where coding workarounds could periodically unsettle volume growth and earnings visibility.

Limited Viability of Category III or Miscellaneous Codes

The company ruled out using a Category III or miscellaneous code as a bridge, arguing that such approaches would exacerbate instability and variability in facility payments. By avoiding a temporary coding patch, Inspire Medical hopes to preserve clarity for hospitals, even if it means enduring a more protracted interim period of professional-fee pressure.

Operational Constraints Around Legacy Product

While some Inspire 4 inventory remains, management emphasized that component obsolescence would limit any attempt to fully restart legacy device production as a workaround. This constrains fallback options and effectively commits the company and its providers to navigating the current reimbursement environment with Inspire 5 at the center.

Tax and Stock-Based Compensation Volatility

The company’s tax outlook is unusually wide, with an expected effective tax rate between 44% and 49% and an adjusted rate of 26% to 28%. Management noted that the tax impact of stock-based compensation, heavily weighted to Q1, can significantly swing reported GAAP tax expense, introducing additional earnings volatility beyond operations.

First Quarter Outlook and Near-Term Earnings Pressure

For Q1 2026, management expects revenue to be roughly flat year over year and guided to a net loss, reflecting coding uncertainty, WISER friction, and higher operating expenses. They anticipate sequential improvement as the year progresses, with the strongest revenue and profit performance targeted for the fourth quarter.

2026 Financial Guidance and Forward Outlook

Revised 2026 guidance calls for revenue of $950 million to $1,000 million, implying 4% to 10% growth and embedding assumptions for a 10% to 50% professional fee haircut. The company projects adjusted operating margins of 6% to 8%, GAAP EPS of $1.23 to $1.81, adjusted EPS of $1.85 to $2.35, capex of $45 million to $50 million, and about 29.4 million diluted shares, with management emphasizing that reimbursement outcomes will dictate where results land within the range.

Inspire Medical’s earnings call painted a story of a high-growth medtech leader now at the mercy of shifting reimbursement rules even as its technology and operations perform strongly. Investors will be watching closely to see whether payer negotiations, coding clarity, and physician economics stabilize fast enough to unlock the upper end of guidance and sustain the company’s growth premium.